Additional information
| Active substance | Tamoxifen (Nolvadex) |
|---|---|
| Chemical name | (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine |
| Side effects | Hot flashes, vaginal discharge, menstrual irregularities, increased risk of endometrial cancer, cataracts, and thromboembolic events such as deep vein thrombosis and pulmonary embolism |
| Effects | Reduces the effect of estrogen in the body, can stimulate ovulation |
| Dosage (sports) | 10-20 mg daily |
| Dosage (medical) | 20 mg daily |
| Half-life | 5 to 7 days |
| Main action | Estrogen receptor antagonist |
| Substance class | Selective Estrogen Receptor Modulator (SERM) |
| Formula | C26H29NO |
| Storage conditions | Store at room temperature away from moisture and heat |
| Concentration | 10 mg/tablet |
| Trade name | Nolvadex, Soltamox |
| Blood pressure | Little to no effect on blood pressure |
| Also known as | TAM, tamoxifen citrate |
| Lab Test | Monitoring liver function tests is recommended |
| Hepatotoxicity | Low, but rare cases of liver cancer and liver-related deaths have been reported |
| Water Retention | No |
| Use in sports | Used to counteract the side effects of anabolic steroids, specifically gynecomastia |
| Manufacturer | DEVA |
| Packing | 30 tablets |
Reviews
There are no reviews yet.